Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer

PURPOSE: Genetic alterations such as activating KRAS and/or inactivating TP53 are thought to be the most common drivers to tumorigenesis. Therefore, we assessed phase I cancer patients with KRAS+/TP53+ mutations. RESULTS: Approximately 8% of patients referred to phase I clinical trials harbored conc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhijie, Piha-Paul, Sarina, Janku, Filip, Subbiah, Vivek, Shi, Naiyi, Gong, Jing, Wathoo, Chetna, Shaw, Kenna, Hess, Kenneth, Broaddus, Russell, Naing, Aung, Hong, David, Tsimberidou, Apostolia M., Karp, Daniel, Yao, James, Meric-Bernstam, Funda, Fu, Siqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464912/
https://www.ncbi.nlm.nih.gov/pubmed/28430579
http://dx.doi.org/10.18632/oncotarget.16840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464912/
https://www.ncbi.nlm.nih.gov/pubmed/28430579
http://dx.doi.org/10.18632/oncotarget.16840

Ejemplares similares